|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2018-06-25 |
A Phase 2a, open label, multicenter, study to evaluate the pharmacokinetic (PK) profile, safety and efficacy of multiple doses of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation (HSCT)
A Phase 2a, Open-label, Multicenter, Study to Evaluate the Pharmacokinetic (PK), Safety and Efficacy of Multiple Doses of Cannabidiol for the Prevention of aGVHD After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
A prospective, open-label, phase 2a study, to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of multiple doses of Cannabidiol (CBD) in participants Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)
100 项与 Kalytera Therapeutics Israel, Ltd. 相关的临床结果
0 项与 Kalytera Therapeutics Israel, Ltd. 相关的专利(医药)
100 项与 Kalytera Therapeutics Israel, Ltd. 相关的药物交易
100 项与 Kalytera Therapeutics Israel, Ltd. 相关的转化医学